TP53 and hypoparathyroidism-retardation-dysmorphism syndrome: Second, CNH endometrial carcinoma is characterized by alterations in the p53 pathway, which was associated with an increased incidence of homologous recombination deficiency (HRD), and in general, HRD tumors might respond to PARP inhibitors (Xiong et al., 2006; Zhou et al., 2007; Tao and Freudenheim, 2010; Zhang et al., 2012).